164 related articles for article (PubMed ID: 28675594)
1. Intravenous Hydroxypropyl β-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial.
Erb-Zohar K; Kropeit D; Scheuenpflug J; Stobernack HP; Hulskotte E; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
Clin Transl Sci; 2017 Nov; 10(6):487-495. PubMed ID: 28675594
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects.
Asari K; Ishii M; Yoshitsugu H; Wakana A; Fancourt C; Yoon E; Furihata K; McCrea JB; Stoch SA; Iwamoto M
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):938-948. PubMed ID: 35238179
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.
Kropeit D; Scheuenpflug J; Erb-Zohar K; Halabi A; Stobernack HP; Hulskotte EGJ; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Sep; 83(9):1944-1953. PubMed ID: 28345163
[TBL] [Abstract][Full Text] [Related]
7. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
8. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
[TBL] [Abstract][Full Text] [Related]
10. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S
Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients.
Prohn M; Viberg A; Zhang D; Dykstra K; Davis C; Macha S; Sabato P; de Alwis D; Iwamoto M; Fancourt C; Cho CR
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):255-267. PubMed ID: 33440077
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers.
Scheuenpflug J; Kropeit D; Erb-Zohar K; Theis JGW; Stobernack HP; McCormick D; Zimmermann H; Rübsamen-Schaeff H
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):6-15. PubMed ID: 34812580
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects.
Kropeit D; McCormick D; Erb-Zohar K; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):16-24. PubMed ID: 34714967
[TBL] [Abstract][Full Text] [Related]
17. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
18. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
19. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
20. Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations.
Mermelstein F; Hamilton DA; Wright C; Lacouture PG; Ramaiya A; Carr DB
Pharmacotherapy; 2013 Oct; 33(10):1012-21. PubMed ID: 23744759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]